Aptevo Therapeutics (NASDAQ:APVO) Upgraded by StockNews.com to “Sell” Rating

StockNews.com upgraded shares of Aptevo Therapeutics (NASDAQ:APVO) to a sell rating in a report issued on Saturday.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO opened at $2.64 on Friday. The stock has a 50 day moving average price of $3.80 and a 200-day moving average price of $166.20. Aptevo Therapeutics has a 52-week low of $2.35 and a 52-week high of $207.33.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.